Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, particularly conditions with high unmet medical need where current treatments are limited by safety, tolerability, or delayed onset of action. The company operates within the biotechnology and pharmaceutical research industries and does not currently generate commercial product revenue, relying instead on capital markets to fund research and development activities.
VistaGen’s primary focus is on intranasal neuroactive therapies designed to provide rapid-onset, non-systemic treatment for psychiatric and neurological disorders. Its lead product candidates target social anxiety disorder (SAD) and major depressive disorder (MDD). The company positions itself around the development of drugs that act via peripheral chemosensory pathways rather than direct systemic exposure, which it believes may reduce side effects and improve patient compliance. VistaGen was founded in 1998 and initially pursued stem cell–based drug discovery before evolving into a CNS-focused clinical development company headquartered in South San Francisco, California.
Business Operations
VistaGen’s operations are centered on drug discovery, clinical development, regulatory strategy, and intellectual property management. The company’s pipeline includes fasedienol (PH94B), an intranasal neuroactive steroid being developed for social anxiety disorder, and PH10, an intranasal formulation of a neuroactive steroid for major depressive disorder. These programs represent the company’s core business activities and principal use of capital.
The company conducts its clinical trials primarily in the United States, utilizing third-party contract research organizations (CROs) and manufacturing partners rather than owning large-scale production facilities. VistaGen controls the underlying intellectual property for its drug candidates and formulations. As a development-stage company, it has no approved products, limited physical assets, and no material revenue from operations, with funding historically derived from equity offerings and other financing activities.
Strategic Position & Investments
VistaGen’s strategic direction emphasizes advancing late-stage clinical development for its lead CNS candidates while seeking regulatory alignment for potential approval pathways. A key growth initiative has been the progression of fasedienol (PH94B) through Phase 3 clinical trials for social anxiety disorder, which the company has identified as a near-term value driver. The company has also pursued clinical proof-of-concept studies for PH10 in major depressive disorder to support broader pipeline optionality.
The company has not reported material acquisitions of other operating companies and does not maintain a diversified investment portfolio. Instead, its strategy centers on internal development of proprietary compounds and potential future licensing or partnership opportunities with larger pharmaceutical companies. VistaGen’s emerging focus on non-systemic, fast-acting CNS treatments differentiates it from traditional oral antidepressant and anxiolytic drug developers, though long-term commercial viability remains dependent on successful clinical and regulatory outcomes.
Geographic Footprint
VistaGen is headquartered in South San Francisco, California, and its corporate and research activities are primarily based in the United States. Clinical trials are conducted at multiple sites across the country, reflecting its domestic operational focus. The company does not currently report significant owned infrastructure or permanent operational facilities outside the U.S.
While VistaGen’s commercial footprint is presently domestic, its drug development strategy is designed with potential global regulatory pathways in mind, including future opportunities in Europe and other international markets. Any international presence to date has been limited to clinical trial participation and regulatory planning rather than direct commercial or manufacturing operations.
Leadership & Governance
VistaGen is led by an executive team with experience in biotechnology finance, drug development, and public company management. The leadership emphasizes disciplined capital allocation, regulatory execution, and advancing CNS therapies through late-stage clinical development. Governance is overseen by a board of directors with backgrounds in life sciences, finance, and corporate strategy.
Key executives include:
- Shawn K. Singh – President and Chief Executive Officer
- Mark A. Smith – Chief Financial Officer
- Bonnie G. Kaplan – Senior Vice President, Corporate Communications
- Adam B. Gardner – Senior Vice President, Legal Affairs and General Counsel
The leadership team has consistently articulated a strategic vision focused on delivering differentiated CNS treatments while maintaining compliance with public company governance and reporting standards under U.S. Securities and Exchange Commission requirements.